Clinical Applications Laboratories Inc.
San Diego, California, 92103, United States
NCT Number: NCT00626184
To assess safety and tolerability of ALV003 in healthy volunteers and patients with Celiac Disease
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
San Diego, California, 92103, United States
A Phase 1, Two Stage, Single Dose, Single-Blind, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
INCLUSION
EXCLUSION
4 dose levels of ALV003 vs placebo
Other names: ALV003 and ALV003 placebo equivalent
Time frame: Throughout
Alvine Pharmaceuticals Inc.
Industry
A Phase 1, Two Stage, Single Dose, Single-Blind, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07063823
Celiac Disease, Digestive System Diseases
Stanford, California, United States
View Trial DetailsNCT07177287
Adults With Celiac Disease, Celiac Disease
Ankara, Turkey (Türkiye)
View Trial DetailsNCT05094232
Celiac Disease, Digestive System Diseases
Terrassa, Barcelona, Spain
View Trial DetailsNCT06178107
Celiac Disease, Digestive System Diseases
Salerno, Italy
View Trial Details